Generalized Anxiety Disorder
Conditions
Keywords
Generalized Anxiety Disorder
Brief summary
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
Detailed description
Termination reason: On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.
Interventions
DRUGPD 0332334
Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must have completed all phases of one of the four preceding double-blind GAD studies. * Female must continue to use adequate birth control methods and have a negative serum pregnancy test within 14 days prior to starting open label treatment.
Exclusion criteria
* Subjects who experienced a serious adverse event during the preceding double-blind efficacy study that was judged to be related to study medication by the investigator or the sponsor's medical monitor. * Individuals who have an ongoing, unresolved, clinically significant medical problem that, in the judgment of the investigator or the sponsor's medical monitor, would make it unsafe for the subject to participate in the study. * Serious suicidal risk per the clinical investigators's judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All discontinuations due to adverse events will be reviewed throughout the trial to assess the safety and tolerability of the compound | Weekly |
| Electrocardiogram will be performed at screening and during follow up visits to assess the safety and tolerability of the compound in terms of clinically significant cardiovascular changes | Screening, Wk 4, Wk 25, Wk 52/EOT |
| The Columbia Suicide Severity Rating scale will be used to assess any suicide related adverse events | As needed |
| The nature, incidence, and duration of adverse events monitored throughout the study by vital signs evaluation at each visit, weight measurements and clinical laboratory monitoring periodically | Screening, Baseline, Wk 4, Wk 12, Wk 25, Wk 38, & Wk 52/EOT |
| The nature, incidence, and duration of adverse events monitored throughout the study by physical exam | Screening, Wk 25 & Wk 52/EOT |
Secondary
| Measure | Time frame |
|---|---|
| The Clinical Global Impression of Severity (CGI-S), and the Daily Diary (DD) will also be used to assess symptoms of GAD over a one year time period. | Baseline, Wk 51 & Wk 52/EOT |
| The Health Care Utilization Questionnaire will be utilized to assess overall Health Care over a one year time period. | Baseline, Wk 12, Wk 25, Wk 38 & Wk 51 |
| The Hamilton Rating Scale for Anxiety (HAM-A) will be used to assess symptoms of Generalized Anxiety Disorder (GAD) over a one year time period. | Baseline, Wk 12, Wk 25, Wk 38, Wk 51 & Wk 52/EOT |
Countries
United States
Outcome results
None listed